Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cenobamate - SK biopharmaceuticals

Drug Profile

Cenobamate - SK biopharmaceuticals

Alternative Names: YKP 3089

Latest Information Update: 08 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SK biopharmaceuticals
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Anxiolytics; Azoles; Carbamates; Mood stabilisers; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Partial epilepsies
  • Phase III Tonic-clonic epilepsy
  • Phase II Bipolar disorders; Neuropathic pain
  • Phase I Anxiety disorders

Most Recent Events

  • 31 Oct 2019 Arvelle plans to launch cenobamate in Europe
  • 13 Aug 2019 SK Life Science initiates a phase III trial for Tonic-clonic epilepsy (Adjunctive therapy) in USA (PO) (NCT03961568)
  • 23 May 2019 SK Life Science plans a phase III trial for Tonic-clonic epilepsy (Adjunctive therapy) in May 2019 (PO) (NCT03961568)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top